Transforming Melanoma Treatment in Manchester – Manchester Cancer Research Centre
Manchester Cancer Research Centre shared a post on LinkedIn:
“Transforming Melanoma Treatment in Manchester
Melanoma is the 5th most common cancer in the UK, but researchers in Manchester are transforming our understanding and treatment of the disease.
The CAcTUS clinical trial at The Christie NHS Foundation Trust is investigating how circulating tumour DNA (ctDNA) can be used to personalise treatment options for patients with advanced melanoma. By identifying the best time to switch between targeted therapy and immunotherapy, the trial hopes to improve patient outcomes and help optimise treatment strategies.
Hear from Professor Paul Lorigan and Dr Rebecca Lee as they discuss how this innovative trial could improve treatment outcomes for melanoma patients in the future.”
More posts featuring Manchester Cancer Research Centre.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023